Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A tumor immunotyping method based on lncRNA markers

An immunophenotyping and anti-tumor immunity technology, applied in the field of tumor immunophenotyping based on lncRNA markers, can solve problems such as the inability to meet individualized immunotherapy and achieve a highly objective effect

Active Publication Date: 2022-05-10
SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional tumor typing, grading, and staging can no longer meet the needs of individualized immunotherapy, especially the prediction of the curative effect and prognosis of the rapidly developing anti-tumor immunotherapy drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A tumor immunotyping method based on lncRNA markers
  • A tumor immunotyping method based on lncRNA markers
  • A tumor immunotyping method based on lncRNA markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Screening lncRNA

[0037] 1. Data source

[0038] 348 patients with bladder cancer treated with the PD-L1 inhibitor atotuzumab from the IMvigor 210 trial (NCT02951767 / NCT02108652, http: / / research-pub.gene.com / IMvigor210CoreBiologies) and 70 patients with melanoma from the TCGA immunologic Treatment cohort (https: / / xenabrowser.net / datapages / ?cohort=GDC%20TCGA%20Melanoma%20(SKCM)&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443). In addition, we included 513 patients with lung adenocarcinoma (LUAD), 493 patients with lung squamous cell carcinoma (LUSC), 1082 patients with breast cancer, 406 patients with bladder cancer and 457 patients with melanoma from multi-cohort studies in TCGA. tumor patients. The data of each research patient includes all of its LncRNA gene expression, CTL expression, tumor microenvironment immune molecule expression and gene expression, and patient survival and prognosis information data.

[0039] 2. lncRNA screening

[0040]...

Embodiment 2

[0047] Verification analysis of embodiment 2 lncRNA in pan-tumor

[0048] For the data of other tumor patients we obtained above, including two groups of melanoma patients (70 cases and 457 cases), 513 cases of lung adenocarcinoma patients, 493 cases of lung squamous cell carcinoma patients, 1082 cases of breast cancer patients and 406 cases For patients with bladder cancer, the process of Example 1 was repeated for validation analysis. The results showed that it had prognostic significance in lung adenocarcinoma, bladder cancer and melanoma (lung adenocarcinoma: HR=0.75, 95% CI (0.57-0.99), P=0.038; bladder cancer: HR=0.68, 95% CI ( 0.51-0.92), P=0.011; melanoma: HR=0.62, 95% CI (0.47-0.81), P Figure 7 ). Therefore, the lncRNA and typing method have significance for anti-tumor immunotherapy efficacy and prognosis prediction of pan-tumor patients.

Embodiment 3

[0049] Example 3 Combined CTL (cytotoxic T lymphocyte) expression type

[0050] According to the current research, it is found that the expression of CTL is closely related to a variety of immune molecules, including a variety of immune cells, immune checkpoints and human leukocyte antigen (see Figure 8 ). Therefore, we tried to analyze the survival prognosis of multiple tumors including bladder cancer, lung adenocarcinoma, breast cancer, Her-2 positive breast cancer, and melanoma, and draw survival curves (such as Figure 9 ). The results showed that the expression of CTL was significantly correlated with the prognosis of patients, and compared with low expression of CTL, patients with high expression of CTL had a significant survival advantage.

[0051] Based on the above, we tried to combine lncRNA grouping and CTL expression to further stratify the bladder cancer patients in the TCGA cohort into four groups, including lncRNA functional type-high expression of CTL, lncRN...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a group of long-chain noncoding RNA (lncRNA) markers for tumor immunophenotyping, including 49 lncRNAs in total. The present invention also provides a method for tumor immunophenotyping based on the above-mentioned lncRNA markers, which divides 49 lncRNAs into groups, and combines the expression of cytotoxic T lymphocytes (CTLs) to further classify patients into hierarchical clusters with immune activation Immune-Active Class, Immune-Exclusion Class, Immune-Dysfunctional Class and Immune-Desert Class. The tumor immune subtype classification method of the present invention has a strong correlation with predicting the overall survival rate and responsiveness of anti-tumor immunotherapy, and has the characteristics of high objectivity, accuracy and repeatability. The establishment of this classification method provides predictive indicators for the efficacy and prognosis of anti-immunotherapy in patients with malignant tumors.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a tumor immunotyping method based on lncRNA markers. Background technique [0002] At present, tumor type, grade and stage are the final three indicators for evaluating tumor biological behavior and diagnosis, among which grade and stage are mainly used for evaluating the biological behavior and prognosis of malignant tumors. [0003] The pathological classification of malignant tumors is based on the degree to which the tumor cells are similar or close to normal tissues to their source tissues. The pathological classification of tumors is an important parameter that can best reflect the biological behavior and morphological characteristics of tumor-derived tissue cells. Tumors of different tissue types have different biological behaviors and invasion and metastasis capabilities. At present, the WHO tumor classification standard is a recognized tumor classification scheme,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/112C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 姚和瑞宋尔卫余运芳区绮云张文达李岸霖
Owner SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com